SupplyManager℠  Become a Customer

  • #1087940
  • 4,588
  • Seqirus USA Inc #33332041810
Afluria® Quadrivalent 2018 Flu Vaccine 60 mcg / 0.5 mL Indicated for People 6 Months of Age and Above Multiple Dose Vial 5 mL

Features
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 6 Months and older
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2017-2018 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2017-2018 Northern Hemisphere influenza season: A/Singapore/GP1908/2015 (H1N1), IVR-180A, A/Hong Kong/4801/2014 (H3N2), NYMC X-263B, B/Phuket/3073/2013 BVR-1B and B/Brisbane/46/2015
  • More …
Container Type
Multiple Dose Vial Prefilled Syringe
Volume
0.5 mL 5 mL
  Log In to Order
or

Professionals Also Viewed


Product Specifications


McKesson #1087940
Manufacturer #33332041810
BrandAfluria® Quadrivalent 2018
ManufacturerSeqirus USA Inc
ApplicationFlu Vaccine
Container TypeMultiple Dose Vial
Dosage FormInjection
NDC Number33332041810
Storage RequirementsRequires Refrigeration
Strength60 mcg / 0.5 mL
TypeIntramuscular
UNSPSC Code51201608
UserIndicated For People 6 Months of Age and Above
Volume5 mL
Features
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 6 Months and older
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2017-2018 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2017-2018 Northern Hemisphere influenza season: A/Singapore/GP1908/2015 (H1N1), IVR-180A, A/Hong Kong/4801/2014 (H3N2), NYMC X-263B, B/Phuket/3073/2013 BVR-1B and B/Brisbane/46/2015
  • The multi-dose presentation contains thimerosal added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury